Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own27.83% Shs Outstand25.52M Perf Week5.71%
Market Cap37.77M Forward P/E- EPS next Y-0.38 Insider Trans0.24% Shs Float18.42M Perf Month-8.07%
Income- PEG- EPS next Q- Inst Own3.35% Short Float0.28% Perf Quarter-11.90%
Sales- P/S- EPS this Y34.43% Inst Trans- Short Ratio0.34 Perf Half Y-24.87%
Book/sh- P/B- EPS next Y5.00% ROA- Short Interest0.05M Perf Year-46.57%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.92 - 3.25 Perf YTD-16.38%
Dividend Est.- P/FCF- EPS past 5Y-53.58% ROI- 52W High-54.46% Beta0.08
Dividend TTM- Quick Ratio- Sales past 5Y0.00% Gross Margin- 52W Low60.85% ATR (14)0.14
Dividend Ex-Date- Current Ratio- EPS Y/Y TTM- Oper. Margin- RSI (14)47.44 Volatility8.32% 10.26%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-39.29% Payout- Rel Volume0.15 Prev Close1.49
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume149.58K Price1.48
SMA200.49% SMA50-9.56% SMA200-9.91% Trades Volume22,615 Change-0.81%
Feb-09-24 07:00AM
Jan-31-24 07:00AM
Jan-08-24 07:00AM
Jan-05-24 09:30AM
Dec-04-23 07:00AM
07:00AM Loading…
Oct-31-23 07:00AM
Oct-09-23 07:00AM
Oct-05-23 07:00AM
Sep-15-23 07:00AM
Sep-14-23 09:15AM
Sep-13-23 04:05PM
Sep-08-23 07:00AM
Aug-30-23 07:00AM
Aug-29-23 07:00AM
09:00AM Loading…
Aug-15-23 09:00AM
Jul-31-23 02:18AM
Jul-28-23 05:25PM
Jul-27-23 11:30AM
Jun-06-23 09:30AM
May-11-23 07:00AM
May-09-23 08:45AM
May-04-23 01:22PM
May-03-23 02:00AM
May-02-23 02:00AM
Apr-25-23 02:00AM
Apr-18-23 10:00AM
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRANCACCIO JOHN PDirectorSep 15Buy1.5016,67025,00516,670Sep 28 06:15 AM